Omicron Threat or Boon to Global Health Systemic Review

Bhupendra Kumar Jain, U. Maheshwarchandrakantham
{"title":"Omicron Threat or Boon to Global Health Systemic Review","authors":"Bhupendra Kumar Jain, U. Maheshwarchandrakantham","doi":"10.1055/s-0042-1751312","DOIUrl":null,"url":null,"abstract":"With a rising number of coronavirus Omicron cases reported across the whole world, starting a third wave of the pandemic in India, the chances are high that it will soon replace Delta as dominant global variant. The trend was already visible in the U.S. where Omicron has taken over Delta as the dominant strain. Omicron is nearly four to five times more infectious than Delta. That is because of mutations in the spike protein which make it easier for the cells to be attacked. Omicron is spreading with faster pace with very little consequences, except for the elderly population and those with comorbidities. Omicron will take a big toll on the vulnerable population with comorbid diseases. Meanwhile, it is a burden as it is causing devastating infections across the world, the World Health Organization has warned that Omicron should not be dismissed as “mild” variant. Increased transmission may lead to more hospitalizations which can lead to increase strain on frontline workers and health care systems and can result in more deaths. While people who recover from coronavirus disease 2019 may develop some natural immunity to the virus, how well the individual is protected from future genetic mutation of coronavirus is still a big question. The definitive evidence for increased remission and immune evasion and vaccine effectiveness is still awaited. This article will highlight few aspect of Omicron including increased transmission, immune evasion, hospitalization, mortality, vaccine effectiveness, and therapeutic drugs effective against the disease.","PeriodicalId":34302,"journal":{"name":"International Journal of Recent Surgical and Medical Sciences","volume":"30 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Recent Surgical and Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1751312","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

With a rising number of coronavirus Omicron cases reported across the whole world, starting a third wave of the pandemic in India, the chances are high that it will soon replace Delta as dominant global variant. The trend was already visible in the U.S. where Omicron has taken over Delta as the dominant strain. Omicron is nearly four to five times more infectious than Delta. That is because of mutations in the spike protein which make it easier for the cells to be attacked. Omicron is spreading with faster pace with very little consequences, except for the elderly population and those with comorbidities. Omicron will take a big toll on the vulnerable population with comorbid diseases. Meanwhile, it is a burden as it is causing devastating infections across the world, the World Health Organization has warned that Omicron should not be dismissed as “mild” variant. Increased transmission may lead to more hospitalizations which can lead to increase strain on frontline workers and health care systems and can result in more deaths. While people who recover from coronavirus disease 2019 may develop some natural immunity to the virus, how well the individual is protected from future genetic mutation of coronavirus is still a big question. The definitive evidence for increased remission and immune evasion and vaccine effectiveness is still awaited. This article will highlight few aspect of Omicron including increased transmission, immune evasion, hospitalization, mortality, vaccine effectiveness, and therapeutic drugs effective against the disease.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
欧米克隆对全球卫生系统评价的威胁或好处
随着全球报告的冠状病毒欧米克隆病例越来越多,在印度开始了第三波大流行,它很有可能很快取代德尔塔病毒,成为占主导地位的全球变种。这种趋势在美国已经很明显,欧米克隆已经取代了德尔塔,成为主要菌株。欧米克隆的传染性几乎是德尔塔病毒的四到五倍。这是因为刺突蛋白的突变使细胞更容易受到攻击。欧米克隆正在以更快的速度传播,除了老年人和那些有合并症的人之外,几乎没有什么后果。“欧米克隆”将对患有合并症的弱势群体造成巨大损失。与此同时,世界卫生组织警告说,它是一种负担,因为它在世界范围内引起毁灭性的感染,不应将欧米克隆视为“轻度”变种。传播增加可能导致更多人住院,这可能导致一线工作人员和卫生保健系统承受更大压力,并可能导致更多死亡。虽然从2019年冠状病毒病中康复的人可能会对该病毒产生一些天然免疫力,但个人在多大程度上免受未来冠状病毒基因突变的影响仍然是一个大问题。目前仍在等待缓解和免疫逃避以及疫苗有效性增加的明确证据。本文将重点介绍欧米克隆的几个方面,包括增加传播、免疫逃避、住院、死亡率、疫苗有效性和有效对抗疾病的治疗药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
32
审稿时长
11 weeks
期刊最新文献
A Cross-Sectional Study of Etiology and Clinico-Hematological Profile of Pancytopenia in Children at Tertiary Care Centre in Western India Effectiveness of Virtual Reality Environment for Post-Operative Pain Management A Study of Blood Viscosity and Inflammatory Biomarkers’ Levels in Bilateral Primary Varicose Veins/Reticular Veins as Predictive Markers A Study to Assess the Burden of Hematological Malignancies at a Tertiary Care Center A Study to Assess the Burden of Hematological Malignancies at a Tertiary Care Center
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1